EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies

Cancer Research

Volumn 69, Issue 20, 2009, Pages 7935-7944

  Yuling, He ^a   Ruijing, Xiao ^a   Li, Li ^a   Xiang, Ji ^a   Rui, Zhou ^a   Yujuan, Wang ^a,b   Lijun, Zhang ^b   Chunxian, Du ^c   Tan, Xinti ^a   Xiao, Wei ^a   Chen, Lang ^a   Jiang, Yanping ^a   Xiong, Tao ^b   Wu, Mengjun ^a   Xiong, Jie ^d   Jin, Youxin ^d   Tan, Jinquan ^a  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ARTICLE; CANCER GRAFT; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TH1 CELL; TH2 CELL; THYMUS; THYROID CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT; VIRUS CARRIER;

ANIMALS; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHIMERA; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; KILLER CELLS, NATURAL; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; THYMUS GLAND;

EID: 70350227251     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0828     Document Type: Article

References (50)

1. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu RevImmunol 2005;23:877-900. (Pubitemid 40563188)
2. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu RevImmunol 2007;25:297-336.
3. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu RevImmunol 2004;22:817-890 (Pubitemid 38680443)
4. Zhou D, Mattner J, Cantu C, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306:1786-1789 (Pubitemid 39601398)
5. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-525 (Pubitemid 40477061)
6. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-529 (Pubitemid 40477062)
7. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-237
8. Smyth MJ, Crowe NY, Pellicci DG, et al. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002;99:1259-1266
9. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene- induced sarcomas. J Exp Med 2002;196:119-127 (Pubitemid 34747317)
10. Cui J, Shin T, Kawano T, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-1626 (Pubitemid 27516281)
11. Terabe M, Swann J, Ambrosino E, et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-1633 (Pubitemid 41815868)
12. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-520
13. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-1752 (Pubitemid 37494166)
14. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000;1:521-525
15. Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res 2006;66:11005-11012
16. Smyth MJ, Godfrey DI. NKT cells and tumor immunity - a double-edged sword. Nat Immunol 2000;1:459-460
17. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007;25:587-617. (Pubitemid 46697918)
18. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
19. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat RevCanc er 2004;4:757-768
20. Duraiswamy J, Sherritt M, Thomson S, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003;101:3150-3156 (Pubitemid 36858009)
21. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555 (Pubitemid 26150682)
22. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004;103:1755-1762
23. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007;110:1326-1329 (Pubitemid 47281432)
24. + T-cell function in Hodgkin lymphoma patients. Blood 2006;108:2280-2289
25. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Health Organization classification of tumours. Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
26. Tatsumi-Tamori A, Yoshizaki T, Miwa T, Furukawa M. Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification. Ann Otol Rhinol Laryngol 2000;109:1125-1129
27. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 1999;95:807-814 (Pubitemid 30062700)
28. Gapin L, Matsuda JL, Surh CD, Kronenberg M. NKT cells derive from double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2001;2:971-978 (Pubitemid 32976171)
29. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;4:1230-1237 (Pubitemid 37540692)
30. Novak EJ, Liu AW, Nepom GT, Kwok WW. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J Clin Invest 1999;104:R63-7.
31. Dunne PJ, Faint JM, Gudgeon NH, et al. Epstein-Barr virus-specific CD8(+) T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential. Blood 2002;100:933-940
32. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 1992;176:169-176
33. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304:104-107 (Pubitemid 38451466)
34. + T cell function but not expansion. Nat Immunol 2002;3:1208-1213
35. + T cells upon CD226 engagement. J Immunol 2005;175:4914-4926
36. van der Vliet HJJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MA. Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol 2008;180:7287-7293
37. Waller EK, Kamel OW, Cleary ML, et al. Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. Blood 1991;78:2650-2665
38. Liu T, Ding Y, Xie W, et al. An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer Res 2007;13:3960-3967 (Pubitemid 47037604)
39. Berzofsky JA, Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 2008;180:3627-3635
40. Ambrosino E, Terabe M, Halder RC, et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-5136
41. + T lymphocytes. Nature 2003;421:852-856
42. + T cells after acute infection. Nat Immunol 2004;5:927-933
43. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-339 (Pubitemid 36433726)
44. + memory T cells. Nature 2006;441:890-893
45. + T cell memory. Science 2002;297:2060-2063
46. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005;434:88-93.
47. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-442 (Pubitemid 34880139)
48. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-1131 (Pubitemid 47281407)
49. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005;201:1503-1517 (Pubitemid 40664093)
50. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006;12:6079-6086 (Pubitemid 44703772)